Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Drug developer announces obesity-therapy patents and a $500,000 private equity investment
March 6th, 2006
FASgen, Inc., announced the award and issuance of the European patent for its index compound C-75 and related weight loss claims, "Inhibition of Fatty Acid Synthase As a Means to Reduce Adipocyte Mass." The inhibition of fatty acid synthase as a means to control obesity has been a cornerstone of FASgen's extensive research into therapeutics to treat obesity. In parallel, the company also announced the award and issuance of its Eurasian patent, "Stimulation of CPT-1 as a Means to Reduce Weight." Stimulation of CPT-1 has been demonstrated to regulate fatty acid oxidation and the consequent weight loss that follows. FASgen's compounds have been shown to work at both the...
Source: Obesity & Diabetes Week (2006-03-06)
|
